Pharmacology & ToxicologybioRxivPreprint
The KRAS G12C Inhibitor Divarasib Stabilizes RBM39 and Antagonizes Aryl-Sulfonamide Degraders
Ssu-Yu Chen, You Zou, Jianli Wu…·Jen‐Tsan Chi
This study identifies RBM39 as a noncovalent target of the KRAS G12C inhibitor divarasib and reveals an RBM39-INSR signaling axis that influences cytotoxicity.
DOI 10.64898/2026.08.16.745134